• Baxdrostat does not meet primary endpoint for BP reduction, possibly due to nonadherence

    13 days ago - By Healio

    NEW ORLEANS - Baxdrostat, an aldosterone synthase inhibitor, did not lower systolic BP compared with placebo at 8 weeks in patients with uncontrolled hypertension, but nonadherence may have been a factor, researchers reported.
    As Healio previously reported, in the phase 2 BrigHTN trial of baxdrostat vs. placebo at 12 weeks in patients with treatment-resistant hypertension, baxdrostat significantly lowered systolic BP at two different doses, 1 mg and 2 mg, compared with placebo. Cardiology Today Intervention Section Editor Deepak L. Bhatt, MD, MPH, FACC, FAHA,
    Read more ...